Compare IVA & BTQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IVA | BTQ |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | France | Canada |
| Employees | 77 | 35 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.8M | 831.4M |
| IPO Year | N/A | N/A |
| Metric | IVA | BTQ |
|---|---|---|
| Price | $4.60 | $3.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | ★ $16.20 | $10.00 |
| AVG Volume (30 Days) | 1.7M | ★ 4.6M |
| Earning Date | 03-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,332.99 |
| Revenue Next Year | $751.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $2.09 |
| 52 Week High | $7.98 | $16.00 |
| Indicator | IVA | BTQ |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 35.97 |
| Support Level | $4.45 | $2.33 |
| Resistance Level | $4.69 | $3.63 |
| Average True Range (ATR) | 0.31 | 0.41 |
| MACD | 0.12 | -0.23 |
| Stochastic Oscillator | 88.85 | 3.39 |
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
BTQ Technologies Corp is engaged in the development of computer-based technology related to post-quantum cryptography, particularly as it applies to blockchain and related technologies, and their protection from the emerging security risk of quantum computing. The company derives revenue from Software licensing. Geographically, the company has a presence in Canada, Taiwan, Australia, and the United States.